Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Skye Bioscience Inc (NQ: SKYE ) 5.560 +0.320 (+6.11%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Skye Bioscience Inc MarketBeat Week in Review – 10/7 - 10/11 October 12, 2024 Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Economy Interest Rates Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar October 09, 2024 Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. Via MarketBeat 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore October 04, 2024 Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure. Via MarketBeat Topics Bankruptcy Exposures Financial Legal Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings August 16, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings August 08, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm August 04, 2024 From The Schall Law Firm Via Business Wire Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity July 24, 2024 From Beacon Biosignals Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
